Clinical Trial Update: Sputum-derived Cellular Targets After Xolair (Omalizumab) [Phase 4]

View source ↗

Summary

Phase 4 trial update on sputum-derived cellular targets after omalizumab (Xolair) in asthma; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: NYU Langone Health | Conditions: Asthma | Phase 4 | Status: TERMINATED | Results posted: 2019-09-30